Cardiovascular Pharmacology: Open Access

LIPID management 2022

International Conference and Expo on Heart and Cardio Care

May 25, 2022 | Webinar

Alnoor Abdulla

FCCP, Vancouver, Canada

Keynote: Cardiovasc Pharm

Abstract:

Higher levels of LDL cholesterol have been linked to increased cardiovascular morbidity and mortality. Lowering LDL levels reduces this morbidity and mortality. STATINS reduce LDL levels and significantly improve adverse cardiovascular outcomes. However Statins have limitations. These include real and perceived side effects, suboptimal adherence, suboptimal pharmacodynamics and their inability to lower LDL to low enough target levels required in high risk patients. This has led to the development of newer medications which can be used in combination with or instead of maximally tolerated doses of Statins. This presentation will review these advances in therapy and put them in perspective in the overall management of lipids.

Biography :

I am a Canadian Cardiologist, with extensive experience in Cardiac Care and Health care delivery in Canada, USA, Pakistan and East Africa. Medicine degree 1975 (UBC), Internal Med.fellowship 1979 (UBC) and Cardiology fellowship in 1982 (UCLA and USC). All through my career I have provided direct tertiary level clinical cardiac care, in multiple major academic centres, public and private practice settings, in large metropolitan cities as well as suburban and rural centres. At the academic centres I was integrally involved in the teaching and research arms of the programs (UCLA, USC, Univ. of Toronto, Univ. of Ottawa and Aga Khan University)